Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US approval of Brintellix first for Lundbeck/Takeda alliance

This article was originally published in Scrip

Executive Summary

The US FDA has granted the first approval worldwide to Lundbeck's Brintellix (vortioxetine) as a treatment for adults with major depressive disorder, paving the way for the multi-modal therapy to become the first commercial product under the Danish firm's strategic alliance with Takeda.

Topics

Related Companies

UsernamePublicRestriction

Register

SC022938

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel